Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Christopher James - Vice President of Investor Relations
Mike Heffernan - Interim President and Chief Executive Officer, Founder & Chairman
Colleen Tupper - Chief Financial Officer
Scott Dreyer - Chief Commercial Officer
Conference Call Participants
David Amsellem - Piper Sandler
Les Sulewski - Truist Securities
Operator
Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note that this conference call is being recorded.
I'll now turn the call over to Christopher James, Vice President of Investor Relations at Collegium. Thank you. You may begin.
Christopher James
Welcome to Collegium Pharmaceutical's second quarter 2024 earnings conference call.
I'm joined today by Mike Heffernan, our Interim President and Chief Executive Officer, Founder and Chairman; Colleen Tupper, our Chief Financial Officer; and Scott Dreyer, our Chief Commercial Officer.
Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional, and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risks that we may not be able to successfully commercialize our products, that we may incur significant expense in doing so, that we may not prevail in current or future litigation pertaining to our business, risks related to our ability to complete the acquisition of Ironshore Therapeutics on the proposed terms and schedule or et al, risks related to our ability to realize the anticipated benefits and synergies of the proposed acquisition of Ironshore, the risk that the business will not be integrated successfully, risks related to negative effects of this announcement or the consummation of proposed acquisition on the market price of our common stock and/or operating results, and risks related to future opportunities and plans for Ironshore. These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today.
Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at collegiumpharma.com.